Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,090 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06942442RecruitingPhase 2
Tebentafusp for advanced clear cell sarcoma
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
Los Angeles, CaliforniaAges 18 years+ - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Stanford, CaliforniaAges 18 years+ - NCT06937034Recruiting
Study of foslevodopa/foscarbidopa for advanced Parkinson's
This study observes how well a new type of levodopa/carbidopa treatment works in real-world practice for people with advanced Parkinson's disease who are already using it. It aims to understand patient experiences and the support program offered by the drug maker.
Graz, StyriaAges 18 years+ - NCT06933069RecruitingPhase 1
Safety study of CMAB017 for advanced solid tumors
This trial tests a new drug called CMAB017 for people with advanced solid tumors who have run out of standard options. The goal is to find a safe dose and see how well it is tolerated.
ShanghaiAges 18–75 - NCT06937905RecruitingPhase 3
Tarlatamab vs chemo for advanced NEC after one prior treatment
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
AngersAges 18 years+ - NCT06932068RecruitingPhase 2
Study of new drug combo for advanced stomach cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
Zhengzhou, HenanAges 18–75 - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06924489Recruiting
3D imaging for better adenoma detection during colonoscopy
This trial tests a 3D imaging device during colonoscopy to see if it helps find more advanced adenomas (precancerous polyps) than standard colonoscopy. If you are scheduled for a diagnostic colonoscopy and haven't had colorectal cancer or polyps removed before, this study might be for you.
Xi'an, ShaanxiAges 18–75 - NCT06926608Recruiting
Helping Latinos quit smoking and get active
This trial is for Hispanic or Latino adults who smoke and want to quit. It tests a program that combines text messages and a wearable activity tracker to help you quit smoking and become more physically active.
Rochester, New YorkAges 18 years+ - NCT06923163Recruiting
How exercise affects your body's metabolism
This study looks at how exercise changes your metabolism in people who are not very active. It may help you understand how physical activity can benefit your health.
Shenzhen, GuangdongAges 18–40 - NCT06930794RecruitingPhase 3
Study of Vebreltinib Plus Chemo for MET-Positive Lung Cancer
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT06916507Recruiting
Early treatment with a new Parkinson's drug
This study tests a new form of Parkinson's medication given through a pump to see how well it works in everyday life for people in the early stages of advanced Parkinson's. It may help control symptoms and improve daily function.
Allensbach, Baden-WurttembergAges 18–67 - NCT06921707Recruiting
WounDx test for healing decisions in large wounds
This trial tests a new tool called WounDx that helps doctors decide the best way to treat large wounds on arms, legs, or buttocks. It may help your wound heal better by guiding your care.
Birmingham, AlabamaAges 18–65 - NCT06917339Recruiting
A study looking at past treatment records
This trial looks back at medical records in the TrakStar database to understand how treatments were given. It does not test a new drug, but helps researchers learn from past treatment experiences.
Malvern, PennsylvaniaAges 5–120 - NCT06911489RecruitingPhase 1
Safety trial of a new targeted therapy for advanced solid tumors
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
ShanghaiAges 18–80 - NCT06907017Recruiting
CorWave left heart pump first-in-human study
This trial tests a new left ventricular assist device (LVAD) for people with advanced heart failure who are not responding to standard treatments and are eligible for a heart transplant. The pump helps the heart circulate blood.
Sydney, New South WalesAges 18–75 - NCT06114004RecruitingPhase 2
Selinexor plus gemcitabine for advanced soft-tissue sarcoma
This trial tests a combination of two drugs, selinexor and gemcitabine, for people with a type of soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) that has spread or cannot be surgically removed and has gotten worse despite at least one prior treatment. The goal is to see if this combination can help shrink or slow the cancer.
Santa Cruz de Tenerife, Canary IslandsAges 18–80 - NCT06904391Recruiting
Helping advanced practice providers start cancer research at their clinics
This study tests whether extra training and mentorship help nurse practitioners and physician assistants lead more cancer research studies at their own clinics. If you are an APP who wants to grow research at your practice, this program could give you the support you need.
Newark, DelawareAges 18 years+ - NCT06909682Recruiting
AI monitoring with wearables for chronic heart failure
This trial tests an AI system that uses wearable devices and mini-invasive tools to monitor people with chronic heart failure. The goal is to detect changes early and help manage the condition at home.
SalernoAges 19 years+ - NCT04221035RecruitingPhase 3
Trial for children with high-risk neuroblastoma testing next steps
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
Sydney, RandwickAges Up to 21 years - NCT06436625Recruiting
Outpatient rehab for lung cancer patients on immunotherapy
This study tests whether a structured outpatient exercise program can help people with non-small cell lung cancer who are already receiving immunotherapy. It is designed for those whose cancer is stable or responding after initial treatment.
ViennaAges 18–120 - NCT06732505RecruitingPhase 1
Ac-225 DOTATATE for SSTR+ GEP-NETs: A Safety Study
This trial tests a new drug, Ac-225 DOTATATE, in people with a type of gut or pancreas tumor (GEP-NET) that has specific proteins (SSTR) on its surface. The goal is to see if it is safe and helps shrink or slow the tumor.
Beijing, Beijing MunicipalityAges 18–80 - NCT06894303Recruiting
Remote programming for cochlear implants in routine follow-up
This study tests if cochlear implants can be adjusted remotely (without visiting the clinic) during regular follow-ups. If you have a compatible implant and sound processor, you may be able to take part from home.
ParisAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,090 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.